Division of Urology, The University of Texas Medical Branch at Galveston, Galveston, Texas.
Department of Surgery, Section of Urology, Medical College of Georgia, Georgia Regents University, Augusta, Georgia.
Cancer. 2018 Aug 1;124(15):3127-3135. doi: 10.1002/cncr.31404. Epub 2018 Apr 16.
Treatments for muscle-invasive bladder cancer are multimodal, complex, and often carry significant risks of physical and psychological morbidity. The objectives of this study were to define the incidence and types of psychiatric illnesses diagnosed after treatment and to determine their impact on survival outcomes.
In total, 3709 patients who were diagnosed with clinical stage T2 through T4a bladder cancer from January 1, 2002, to December 31, 2011, from the Surveillance, Epidemiology, and End Results-Medicare were analyzed. Multivariable analysis and Cox proportional-hazards models were used to determine the predictors associated with psychiatric diagnosis and impact on survival outcomes.
Of 3709 patients, 1870 (50.4%) were diagnosed with posttreatment psychiatric disorders. Patients who underwent radical cystectomy were identified as being at significantly greater risk of having a posttreatment psychiatric illness compared with those who received radiotherapy and/or chemotherapy (hazard ratio [HR], 1.19; 95% confidence interval [CI], 1.07-1.31; P = .001). In adjusted analyses, diagnosis of a psychiatric disorder resulted in significantly worse overall survival (HR, 2.80; 95% CI, 2.47-3.17; P < .001) and cancer-specific survival (HR, 2.39; 95% CI, 2.05-2.78; P < .001).
One-half of patients with muscle-invasive bladder cancer who underwent treatment were diagnosed with a psychiatric disorder, which resulted in worse survival outcomes compared with patients who did not have a posttreatment psychiatric diagnosis. This information can be used to inform interventions to educate patients with muscle-invasive bladder cancer regarding the impact of different treatments on mental health. Cancer 2018. © 2018 American Cancer Society.
肌层浸润性膀胱癌的治疗方法是多模式的、复杂的,并且往往会带来身体和心理发病的重大风险。本研究的目的是确定治疗后诊断出的精神疾病的发病率和类型,并确定它们对生存结果的影响。
总共分析了 2002 年 1 月 1 日至 2011 年 12 月 31 日期间,来自监测、流行病学和最终结果-医疗保险的临床分期 T2 至 T4a 膀胱癌的 3709 例患者。使用多变量分析和 Cox 比例风险模型来确定与诊断为精神疾病相关的预测因素及其对生存结果的影响。
在 3709 例患者中,有 1870 例(50.4%)被诊断为治疗后精神障碍。与接受放疗和/或化疗的患者相比,接受根治性膀胱切除术的患者被认为有更高的患治疗后精神疾病的风险(风险比 [HR],1.19;95%置信区间 [CI],1.07-1.31;P=.001)。在调整后的分析中,诊断为精神障碍会导致整体生存(HR,2.80;95%CI,2.47-3.17;P<.001)和癌症特异性生存(HR,2.39;95%CI,2.05-2.78;P<.001)明显恶化。
接受治疗的肌层浸润性膀胱癌患者中有一半被诊断患有精神疾病,与未诊断出治疗后精神疾病的患者相比,其生存结果更差。这些信息可以用于告知患有肌层浸润性膀胱癌的患者不同治疗方法对心理健康的影响,以便采取干预措施。癌症 2018. ©2018 美国癌症协会。